231 related articles for article (PubMed ID: 30466755)
1. Is it time to routinely incorporate MRD into practice?
Ravandi F
Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy.
Appelbaum FR
Best Pract Res Clin Haematol; 2018 Dec; 31(4):405-409. PubMed ID: 30466757
[TBL] [Abstract][Full Text] [Related]
3. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
Sun Y; Zhu G; Zhong H
Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
[TBL] [Abstract][Full Text] [Related]
5. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
Nagler A; Baron F; Labopin M; Polge E; Esteve J; Bazarbachi A; Brissot E; Bug G; Ciceri F; Giebel S; Gilleece MH; Gorin NC; Lanza F; Peric Z; Ruggeri A; Sanz J; Savani BN; Schmid C; Shouval R; Spyridonidis A; Versluis J; Mohty M
Bone Marrow Transplant; 2021 Jan; 56(1):218-224. PubMed ID: 32724200
[TBL] [Abstract][Full Text] [Related]
7. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
8. Measurement of Residual Disease in Acute Myeloid Leukemia.
Vedula RS; Lindsley RC
Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
[TBL] [Abstract][Full Text] [Related]
9. Widespread use of measurable residual disease in acute myeloid leukemia practice.
Epstein-Peterson ZD; Devlin SM; Stein EM; Estey E; Tallman MS
Leuk Res; 2018 Apr; 67():92-98. PubMed ID: 29482173
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease in acute myelogenous leukemia.
Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
[TBL] [Abstract][Full Text] [Related]
11. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
12. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
13. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract][Full Text] [Related]
14. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
Tomlinson B; Lazarus HM
Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
[TBL] [Abstract][Full Text] [Related]
15. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
16. Evaluating measurable residual disease in acute myeloid leukemia.
Ravandi F; Walter RB; Freeman SD
Blood Adv; 2018 Jun; 2(11):1356-1366. PubMed ID: 29895626
[TBL] [Abstract][Full Text] [Related]
17. MRD in AML: it is time to change the definition of remission.
Ossenkoppele GJ; Schuurhuis GJ
Best Pract Res Clin Haematol; 2014; 27(3-4):265-71. PubMed ID: 25455276
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of measurable residual disease detection in AML in morphologic remission.
Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A
Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
Buccisano F; Maurillo L; Del Principe MI; Di Veroli A; De Bellis E; Biagi A; Zizzari A; Rossi V; Rapisarda V; Amadori S; Voso MT; Lo-Coco F; Arcese W; Venditti A
Expert Rev Hematol; 2018 Apr; 11(4):307-313. PubMed ID: 29495904
[TBL] [Abstract][Full Text] [Related]
20. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?
Luskin MR; Stone RM
J Oncol Pract; 2017 Aug; 13(8):471-480. PubMed ID: 28796964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
